Cargando…

Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells

Combination regiments involving platinum anticancer drugs and agents with unrelated mechanisms of action are a subject of widespread interest. Here, we show that synergistic toxic action in cancer cells of combinations of antitumor platinum drug carboplatin and effective PARP inhibitor olaparib is c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novohradsky, Vojtech, Zajac, Juraj, Vrana, Oldrich, Kasparkova, Jana, Brabec, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033346/ https://www.ncbi.nlm.nih.gov/pubmed/29983873 http://dx.doi.org/10.18632/oncotarget.25466

Ejemplares similares

Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells
por: Novohradsky, Vojtech, et al.
Publicado: (2018)

An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis
por: Novohradsky, Vojtech, et al.
Publicado: (2019)

Gallium(III) Complex with Cloxyquin Ligands Induces Ferroptosis in Cancer Cells and Is a Potent Agent against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells
por: Hreusova, Monika, et al.
Publicado: (2022)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates
por: Novohradsky, Vojtech, et al.
Publicado: (2017)

Ruthenium(II)–Tris-pyrazolylmethane Complexes Inhibit Cancer Cell Growth by Disrupting Mitochondrial Calcium Homeostasis
por: Cervinka, Jakub, et al.
Publicado: (2022)

Metallohelix vectors for efficient gene delivery via cationic DNA nanoparticles
por: Malina, Jaroslav, et al.
Publicado: (2022)

Cyclometalated Benzimidazole Osmium(II) Complexes with Antiproliferative Activity in Cancer Cells Disrupt Calcium Homeostasis
por: Hernández-García, Alba, et al.
Publicado: (2023)

Glycoconjugated Metallohelices have Improved Nuclear Delivery and Suppress Tumour Growth In Vivo
por: Song, Hualong, et al.
Publicado: (2020)

Novel cis-Pt(II) Complexes with Alkylpyrazole Ligands: Synthesis, Characterization, and Unusual Mode of Anticancer Action
por: Kasparkova, Jana, et al.
Publicado: (2022)

Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes
por: Davarpanah, Fereshteh, et al.
Publicado: (2018)

Mechanism of the formation of DNA–protein cross-links by antitumor cisplatin
por: Chválová, Kateřina, et al.
Publicado: (2007)

Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional Pt(II) complexes
por: Malina, Jaroslav, et al.
Publicado: (2009)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells
por: Novohradsky, Vojtech, et al.
Publicado: (2023)

Carboplatin-Induced Hypersensitivity Reaction
por: Potolidis, Evangelos, et al.
Publicado: (2012)

Hypersensitivity to Carboplatin in Children with Malignancy
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics
por: Zhuang, Wei, et al.
Publicado: (2022)

Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group
por: Lai, Chyong-Huey, et al.
Publicado: (2019)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

Walking of antitumor bifunctional trinuclear Pt(II) complex on double-helical DNA
por: Malina, Jaroslav, et al.
Publicado: (2011)

Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes
por: Brabec, Viktor, et al.
Publicado: (2016)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
por: Gibbs, D D, et al.
Publicado: (2002)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015)

PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)

Chiral discrimination in platinum anticancer drugs.
por: Benedetti, Michele, et al.
Publicado: (2002)

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
por: Perez-Fidalgo, J.A., et al.
Publicado: (2021)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action
por: Raveendran, Raji, et al.
Publicado: (2016)

Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration
por: Sangrà, Marc, et al.
Publicado: (2017)

Maleimide-Decorated PEGylated Mucoadhesive Liposomes for Ocular Drug Delivery
por: Moiseev, Roman V., et al.
Publicado: (2022)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of Antitumor trans-[PtCl(2)(NH(3))(thiazole)]
por: Marini, Victoria, et al.
Publicado: (2005)

Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
por: Tai, Yu-Hsiao, et al.
Publicado: (2017)

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
por: Perez-Fidalgo, J Alejandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j41fonva03pou6ggh6p95j0hea